Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 8/20 | 0.94 |
| ▸ | RAB9A | P51151 | 8/20 | 0.94 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.94 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.94 |
| ▸ | TP53 | P04637 | 4/20 | 0.94 |
| ▸ | PKM | P14618 | 1/20 | 0.94 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.94 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.88 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.84 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.83 |
| ▸ | KCNK9 | Q9NPC2 | 2/20 | 0.77 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.77 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.72 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.72 |
| ▸ | RELA | Q04206 | 1/20 | 0.72 |
| ▸ | HTT | P42858 | 1/20 | 0.71 |
| ▸ | TSHR | P16473 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4256368 | 0.97 | NPC1 (1.00) | NPC1RAB9ASMN1; SMN2ALDH1A1TP53 | |
| SCHEMBL4252397 | 0.94 | NPC1 (0.83) | NPC1RAB9ASMN1; SMN2ALDH1A1TP53 | |
| SCHEMBL31179863 | 0.94 | NPC1 (0.83) | NPC1RAB9ASMN1; SMN2ALDH1A1TP53 | |
| SCHEMBL29800540 | 0.93 | NPC1 (1.00) | NPC1RAB9ASMN1; SMN2ALDH1A1TP53 | |
| SCHEMBL2176828 | 0.93 | NPC1 (1.00) | NPC1RAB9ASMN1; SMN2ALDH1A1TP53 | |
| SCHEMBL4248632 | 0.92 | RAB9A (0.81) | NPC1RAB9ASMN1; SMN2ALDH1A1TP53 | |
| SCHEMBL13213708 | 0.92 | NPC1 (0.81) | NPC1RAB9ASMN1; SMN2ALDH1A1TP53 | |
| SCHEMBL4251080 | 0.92 | NPC1 (0.81) | NPC1RAB9ASMN1; SMN2ALDH1A1TP53 | |
| SCHEMBL4250977 | 0.92 | NPC1 (0.81) | NPC1RAB9ASMN1; SMN2ALDH1A1TP53 | |
| SCHEMBL94789 | 0.92 | NPC1 (0.81) | NPC1RAB9ASMN1; SMN2ALDH1A1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11779583-B2 | Tricyclic amino containing compounds for treatment or prevention of symptoms associated with endocrine dysfunction | EMORY UNIVERSITY (US) | 2023-10-10 | — | — | US | disclosed |
| US-20210401836-A1 | TRICYCLIC AMINO CONTAINING COMPOUNDS FOR TREATMENT OR PREVENTION OF SYMPTOMS ASSOCIATED WITH ENDOCRINE DYSFUNCTION | EMORY UNIVERSITY (US) | 2021-12-30 | — | — | US | disclosed |
| US-10632120-B2 | Tricyclic amino containing compounds for treatment or prevention of symptoms associated with endocrine dysfunction | EMORY UNIVERSITY (US) | 2020-04-28 | — | — | US | disclosed |
| US-20190322633-A1 | STROMAL DERIVED FACTOR INHIBITION AND CXCR4 BLOCKADE | BLAINE, THEODORE A. | 2019-10-24 | — | — | US | disclosed |
| US-20180104243-A1 | Tricyclic Amino Containing Compounds for Treatment or Prevention of Symptoms Associated with Endocrine Dysfunction | EMORY UNIVERSITY | 2018-04-19 | — | — | US | disclosed |
| EP-2776387-B1 | TRICYCLIC AMINO CONTAINING COMPOUNDS FOR TREATMENT OR PREVENTION OF SYMPTOMS ASSOCIATED WITH ENDOCRINE DYSFUNCTION | UNIV EMORY (US) | 2017-02-01 | — | — | EP | disclosed |
| US-20160058761-A1 | Tricyclic Amino Containing Compounds for Treatment or Prevention of Symptoms Associated with Endocrine Dysfunction | METASTATIX, INC. | 2016-03-03 | — | — | US | disclosed |
| US-20160002174-A1 | CXCR4 Antagonists for the Treatment of Medical Disorders | EMORY UNIVERSITY | 2016-01-07 | — | — | US | disclosed |
| US-9205085-B2 | Tricyclic amino containing compounds for treatment or prevention of symptoms associated with endocrine dysfunction | EMORY UNIVERSITY (US) | 2015-12-08 | — | — | US | disclosed |
| US-20140206629-A1 | Stromal Derived Factor Inhibition And CXCR4 Blockade | RHODE ISLAND HOSPITAL (US) | 2014-07-24 | — | — | US | disclosed |
| US-20140206629-A1 | Stromal Derived Factor Inhibition And CXCR4 Blockade | RHODE ISLAND HOSPITAL (US) | 2014-07-24 | — | — | US | disclosed |
| US-20140039187-A1 | CXCR4 ANTAGONISTS FOR THE TREATMENT OF MEDICAL DISORDERS | EMORY UNIVERSITY | 2014-02-06 | — | — | US | disclosed |
| WO-2013070660-A1 | TRICYCLIC AMINO CONTAINING COMPOUNDS FOR TREATMENT OR PREVENTION OF SYMPTOMS ASSOCIATED WITH ENDOCRINE DYSFUNCTION | EMORY UNIVERSITY (US) | 2013-05-16 | — | — | WO | disclosed |
| US-8114884-B2 | CXCR4 antagonists for the treatment of medical disorders | EMORY UNIVERSITY (US) | 2012-02-14 | — | — | US | disclosed |
| US-8114884-B2 | CXCR4 antagonists for the treatment of medical disorders | EMORY UNIVERSITY (US) | 2012-02-14 | — | — | US | disclosed |
| US-8008312-B2 | CXCR4 antagonists for the treatment of HIV infection | EMORY UNIVERSITY (US) | 2011-08-30 | — | — | US | disclosed |
| US-8008312-B2 | CXCR4 antagonists for the treatment of HIV infection | EMORY UNIVERSITY (US) | 2011-08-30 | — | — | US | disclosed |
| US-20070054930-A1 | CXCR4 antagonists for the treatment of medical disorders | EMORY UNIVERSITY | 2007-03-08 | — | — | US | disclosed |
| US-20070054930-A1 | CXCR4 antagonists for the treatment of medical disorders | EMORY UNIVERSITY | 2007-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140206629-A1 | Stromal Derived Factor Inhibition And CXCR4 Blockade | CXCL12, CXCR4, SDF4 | NPC1 2543/4885RAB9A 2714/4885SMN1; SMN2 4282/4885 |
| US-20210401836-A1 | TRICYCLIC AMINO CONTAINING COMPOUNDS FOR TREATMENT OR PREVENTION OF SYMPTOMS ASSOCIATED WITH ENDOCRINE DYSFUNCTION | SHBG, ABAT, GLS | NPC1 3425/4885RAB9A 3268/4885SMN1; SMN2 4762/4885 |
| US-20190322633-A1 | STROMAL DERIVED FACTOR INHIBITION AND CXCR4 BLOCKADE | CXCL12, CXCR4, SDF4 | NPC1 2543/4885RAB9A 2714/4885SMN1; SMN2 4282/4885 |
| US-10632120-B2 | Tricyclic amino containing compounds for treatment or prevention of symptoms associated with endocrine dysfunction | SHBG, ABAT, GLS | NPC1 3425/4885RAB9A 3268/4885SMN1; SMN2 4762/4885 |
| US-20070054930-A1 | CXCR4 antagonists for the treatment of medical disorders | CXCR4, CXCL12, CXCR1 | NPC1 505/4885RAB9A 2008/4885SMN1; SMN2 3060/4885 |
| US-20160058761-A1 | Tricyclic Amino Containing Compounds for Treatment or Prevention of Symptoms Associated with Endocrine Dysfunction | SHBG, ABAT, GLS | NPC1 3425/4885RAB9A 3268/4885SMN1; SMN2 4762/4885 |
| US-11779583-B2 | Tricyclic amino containing compounds for treatment or prevention of symptoms associated with endocrine dysfunction | SHBG, ABAT, GLS | NPC1 3425/4885RAB9A 3268/4885SMN1; SMN2 4762/4885 |
| US-20160002174-A1 | CXCR4 Antagonists for the Treatment of Medical Disorders | CXCR4, CXCL12, CXCR1 | NPC1 505/4885RAB9A 2008/4885SMN1; SMN2 3060/4885 |
| US-20140039187-A1 | CXCR4 ANTAGONISTS FOR THE TREATMENT OF MEDICAL DISORDERS | CXCR4, CXCL12, CXCR1 | NPC1 505/4885RAB9A 2008/4885SMN1; SMN2 3060/4885 |
| US-20180104243-A1 | Tricyclic Amino Containing Compounds for Treatment or Prevention of Symptoms Associated with Endocrine Dysfunction | SHBG, ABAT, GLS | NPC1 3425/4885RAB9A 3268/4885SMN1; SMN2 4762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.